US006444228B1

(12) **United States Patent**
Baugh et al.

(10) **Patent No.: US 6,444,228 B1**
(45) **Date of Patent: Sep. 3, 2002**

(54) **AUTOLOGOUS FIBRIN SEALANT AND METHOD FOR MAKING THE SAME**

(75) Inventors: **Robert F. Baugh**, Parker; **Lisa M. Lim**, Aurora; **Julie S. Johnston**, Highlands Ranch; **John G. Rivera**, Aurora, all of CO (US)

(73) Assignee: **Medtronic, Inc.**, Minneapolis, MN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 778 days.

(21) Appl. No.: **09/063,338**

(22) Filed: **Apr. 20, 1998**

Related U.S. Application Data

(63) Continuation-in-part of application No. 08/640,278, filed on Apr. 30, 1996, now abandoned.

(51) **Int. Cl.**[7] **A61K 35/16**
(52) **U.S. Cl.** **424/530**; 424/529; 424/531; 424/532
(58) **Field of Search** 424/529, 530, 424/531, 532

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,627,879	A		12/1986	Rose	
5,354,682	A		10/1994	Kingdon et al.	
5,391,380	A	*	2/1995	Barrow et al.	424/570
5,510,102	A	*	4/1996	Cochrum	424/78.08
5,585,007	A	*	12/1996	Antanavich et al.	210/782
5,607,694	A		3/1997	Marx	
5,643,192	A	*	7/1997	Hirsh et al.	604/4
5,788,662	A	*	8/1998	Antanavich et al.	604/6

FOREIGN PATENT DOCUMENTS

EP	0 443 724	8/1991
FR	2 696 095	4/1994
WO	WO 97/29792	8/1997

OTHER PUBLICATIONS

Marieb, E., Human Anatomy and Physiology, 2d Ed., Benjamin/Cummings, California, 1992, pp. 596–596.*

"Simultaneous Occurrence of Human Antibodies Directed against Fibrinogen, Thrombin, and Factor V Following Exposure to Bovine Thrombin: Effects on Blood Coagulation, Protein C Activation and Platelet Function," Vibhuti D. Chouhan, Raul A. De La Cadena, Chandrasekaran Nagaswami, John W. Weisel, Mehdi Kajani, and A. Koneti Rao, *Thrombosis and Haemostasis*, 77(2):343–9 (1997).

"Severe Bleeding due to Factor V Inhibitor after Repeated Operations Using Fibrin Sealant containing Bovine Thrombin," W. Muntean, W. Zenz, G. Edlinger, and A Beitzke, *Thrombosis and Haemostasis*, 77:1223 (1997).

Postoperative Bleeding Induced by Topical Bovine Thrombin: Report of Two Cases, Robert J. Christie, MD, Leonthena Carrington, BS, and Barbara Alving, MD, Surgergy, 121(6):708–710 (Jun. 1977).

"Fibrin Sealant: Summary of a Conference on Characteristics and Clinical Uses," B.M. Alving, M.J. Weinstein, J.S. Finlayson, J.E. Menitove, and J.C. Fratantoni, Transfusion, 35:783–790 (1995).

"Inhibitor to Factor V after Exposure to Fibrin Sealant During Cardiac Surgery in a Two–Year–Old Child," W. Muntean, W. Zenz, K. Finging, G. Zobel, and A Beitzke, *Acta Paediatr,* 83:84–7 (1994).

"Immunization by Bovine Thrombin Used With Fibrin Glue During Cardiovascular Operations," Micheline Berruyer, BS, Jean Amiral, PhD, Patrick Ffrench, MD, Jean Belleville, MD, Olivier Bastien, MD, Jean Clerc,MD, Alain Kassir, MD, Susanne Estanove, MD, and Marc Dechavanne, MD, *The Journey of Thoracic and Cardiovascular Surgery,* 105(5):892–897 (May 1993).

"An Anaphylactic Reaction to Topical Fibrin Glue," Hiromasa Mitsuhata, MD, Yuji Horiguchi, MD, Kazuhiko Saitoh, MD, Hirokazu Fukuda, MD, Yosihiro Hirabayasi, MD, Hideaki Togashi, MD, and Reiju Shimizu, MD, *Anesthesiology,* 81(4):1074–1077 (Oct. 1994).

"Anaphylactic Reaction to Topical Bovine Thrombin," David M. Rothenberg, MD, and James N. Moy, MD, *Anesthesiology,* 78(4):779–782 (Apr. 1993).

"Clinical Significance of Antibodies to Bovine and Human Thrombin and Factor V After Surgical Use of Bovine Thrombin," Samuel I. Rapaport, MD, Ariella Zivelin, M.Sc., Robert A. Minow, MD, Christine S. Hunter, MD, and Kathleen Donnelly, MS, A.J.C.P., 97(1):84–91 (Jan. 1992).

"Development of Antibodies to Thrombin and Factor V With Recurrent Bleeding in a Patient Exposed to Topical Bovine Thrombin," James L. Zehnder, and Lawrence L.K. Leung, *Blood,* 76(10):2011–1016 (Nov.15, 1990).

(List continued on next page.)

Primary Examiner—Jean C. Witz
(74) *Attorney, Agent, or Firm*—Steven C. Petersen; Hogan & Hartson, LLP; Sarah S. O'Rourke

(57) **ABSTRACT**

In general, the present invention relates to a two-phase method for forming an autologous bioadhesive sealant composition or fibrin glue wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. First, a platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. The platelet rich plasma and platelet poor plasma are then divided into two portions. To the first portion, which is used in phase-one, a compound that reverses the effect of the anticoagulant is added, and a clot is allowed to form. The clot is then triturated and the resulting serum, containing autologous thrombin, is collected. The serum obtained from phase-one is then mixed with the second portion of the platelet rich plasma or platelet poor plasma, used in phase-two, to form the bioadhesive sealant of the present invention.

66 Claims, 7 Drawing Sheets